BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Furuyama W, Reynolds P, Haddock E, Meade-White K, Quynh Le M, Kawaoka Y, Feldmann H, Marzi A. A single dose of a vesicular stomatitis virus-based influenza vaccine confers rapid protection against H5 viruses from different clades. NPJ Vaccines 2020;5:4. [PMID: 31934358 DOI: 10.1038/s41541-019-0155-z] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 10.5] [Reference Citation Analysis]
Number Citing Articles
1 Furuyama W, Shifflett K, Pinski AN, Griffin AJ, Feldmann F, Okumura A, Gourdine T, Jankeel A, Lovaglio J, Hanley PW, Thomas T, Clancy CS, Messaoudi I, O'Donnell KL, Marzi A. Rapid protection from COVID-19 in nonhuman primates vaccinated intramuscularly but not intranasally with a single dose of a recombinant vaccine. bioRxiv 2021:2021. [PMID: 33501447 DOI: 10.1101/2021.01.19.426885] [Cited by in Crossref: 7] [Article Influence: 7.0] [Reference Citation Analysis]
2 Scher G, Schnell MJ. Rhabdoviruses as vectors for vaccines and therapeutics. Curr Opin Virol 2020;44:169-82. [PMID: 33130500 DOI: 10.1016/j.coviro.2020.09.003] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
3 O’donnell KL, Gourdine T, Fletcher P, Shifflett K, Furuyama W, Clancy CS, Marzi A. VSV-Based Vaccines Reduce Virus Shedding and Viral Load in Hamsters Infected with SARS-CoV-2 Variants of Concern. Vaccines 2022;10:435. [DOI: 10.3390/vaccines10030435] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
4 Case JB, Rothlauf PW, Chen RE, Kafai NM, Fox JM, Shrihari S, McCune BT, Harvey IB, Smith B, Keeler SP, Bloyet LM, Winkler ES, Holtzman MJ, Fremont DH, Whelan SPJ, Diamond MS. Replication-competent vesicular stomatitis virus vaccine vector protects against SARS-CoV-2-mediated pathogenesis. bioRxiv 2020:2020. [PMID: 32676597 DOI: 10.1101/2020.07.09.196386] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 4.5] [Reference Citation Analysis]
5 Case JB, Rothlauf PW, Chen RE, Kafai NM, Fox JM, Smith BK, Shrihari S, McCune BT, Harvey IB, Keeler SP, Bloyet LM, Zhao H, Ma M, Adams LJ, Winkler ES, Holtzman MJ, Fremont DH, Whelan SPJ, Diamond MS. Replication-Competent Vesicular Stomatitis Virus Vaccine Vector Protects against SARS-CoV-2-Mediated Pathogenesis in Mice. Cell Host Microbe 2020;28:465-474.e4. [PMID: 32798445 DOI: 10.1016/j.chom.2020.07.018] [Cited by in Crossref: 62] [Cited by in F6Publishing: 61] [Article Influence: 31.0] [Reference Citation Analysis]
6 Kim GN, Choi JA, Wu K, Saeedian N, Yang E, Park H, Woo SJ, Lim G, Kim SG, Eo SK, Jeong HW, Kim T, Chang JH, Seo SH, Kim NH, Choi E, Choo S, Lee S, Winterborn A, Li Y, Parham K, Donovan JM, Fenton B, Dikeakos JD, Dekaban GA, Haeryfar SMM, Troyer RM, Arts EJ, Barr SD, Song M, Kang CY. A vesicular stomatitis virus-based prime-boost vaccination strategy induces potent and protective neutralizing antibodies against SARS-CoV-2. PLoS Pathog 2021;17:e1010092. [PMID: 34914812 DOI: 10.1371/journal.ppat.1010092] [Reference Citation Analysis]
7 Stubbs SH, Cornejo Pontelli M, Mishra N, Zhou C, de Paula Souza J, Mendes Viana RM, Lipkin WI, Knipe DM, Arruda E, Whelan SPJ. Vesicular Stomatitis Virus Chimeras Expressing the Oropouche Virus Glycoproteins Elicit Protective Immune Responses in Mice. mBio 2021;12:e0046321. [PMID: 34340542 DOI: 10.1128/mBio.00463-21] [Reference Citation Analysis]
8 Lundstrom K. Self-Replicating RNA Viruses for Vaccine Development against Infectious Diseases and Cancer. Vaccines (Basel) 2021;9:1187. [PMID: 34696295 DOI: 10.3390/vaccines9101187] [Reference Citation Analysis]
9 Kennedy RB, Ovsyannikova IG, Poland GA. Update on Influenza Vaccines: Needs and Progress. J Allergy Clin Immunol Pract 2021;9:3599-603. [PMID: 34416408 DOI: 10.1016/j.jaip.2021.08.003] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
10 Baldo A, Leunda A, Willemarck N, Pauwels K. Environmental Risk Assessment of Recombinant Viral Vector Vaccines against SARS-Cov-2. Vaccines (Basel) 2021;9:453. [PMID: 34063733 DOI: 10.3390/vaccines9050453] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
11 Case JB, Rothlauf PW, Chen RE, Liu Z, Zhao H, Kim AS, Bloyet LM, Zeng Q, Tahan S, Droit L, Ilagan MXG, Tartell MA, Amarasinghe G, Henderson JP, Miersch S, Ustav M, Sidhu S, Virgin HW, Wang D, Ding S, Corti D, Theel ES, Fremont DH, Diamond MS, Whelan SPJ. Neutralizing Antibody and Soluble ACE2 Inhibition of a Replication-Competent VSV-SARS-CoV-2 and a Clinical Isolate of SARS-CoV-2. Cell Host Microbe 2020;28:475-485.e5. [PMID: 32735849 DOI: 10.1016/j.chom.2020.06.021] [Cited by in Crossref: 140] [Cited by in F6Publishing: 137] [Article Influence: 70.0] [Reference Citation Analysis]
12 Lei H, Gao T, Cen Q, Peng X. Haemagglutinin displayed on the surface of Lactococcus lactis confers broad cross-clade protection against different H5N1 viruses in chickens. Microb Cell Fact 2020;19:193. [PMID: 33059676 DOI: 10.1186/s12934-020-01453-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
13 O'Donnell KL, Clancy CS, Griffin AJ, Shifflett K, Gourdine T, Thomas T, Long CM, Furuyama W, Marzi A. Optimization of Single-Dose VSV-Based COVID-19 Vaccination in Hamsters. Front Immunol 2021;12:788235. [PMID: 35069564 DOI: 10.3389/fimmu.2021.788235] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
14 Furuyama W, Shifflett K, Pinski AN, Griffin AJ, Feldmann F, Okumura A, Gourdine T, Jankeel A, Lovaglio J, Hanley PW, Thomas T, Clancy CS, Messaoudi I, O'Donnell KL, Marzi A. Rapid Protection from COVID-19 in Nonhuman Primates Vaccinated Intramuscularly but Not Intranasally with a Single Dose of a Vesicular Stomatitis Virus-Based Vaccine. mBio 2022;:e0337921. [PMID: 35012339 DOI: 10.1128/mbio.03379-21] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
15 Farzani TA, Chov A, Herschhorn A. A protocol for displaying viral envelope glycoproteins on the surface of vesicular stomatitis viruses. STAR Protoc 2020;1:100209. [PMID: 33377103 DOI: 10.1016/j.xpro.2020.100209] [Reference Citation Analysis]
16 Pinski AN, Messaoudi I. To B or Not to B: Mechanisms of Protection Conferred by rVSV-EBOV-GP and the Roles of Innate and Adaptive Immunity. Microorganisms 2020;8:E1473. [PMID: 32992829 DOI: 10.3390/microorganisms8101473] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
17 Furuyama W, Marzi A. Development of an Enzyme-Linked Immunosorbent Assay to Determine the Expression Dynamics of Ebola Virus Soluble Glycoprotein during Infection. Microorganisms 2020;8:E1535. [PMID: 33036194 DOI: 10.3390/microorganisms8101535] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
18 Pinski AN, Messaoudi I. Therapeutic vaccination strategies against EBOV by rVSV-EBOV-GP: the role of innate immunity. Curr Opin Virol 2021;51:179-89. [PMID: 34749265 DOI: 10.1016/j.coviro.2021.10.007] [Reference Citation Analysis]
19 Oâ Donnell KL, Clancy CS, Griffin AJ, Shifflett K, Gourdine T, Thomas T, Long CM, Furuyama W, Marzi A. Optimization of single dose VSV-based COVID-19 vaccination in hamsters. bioRxiv 2021:2021. [PMID: 34518839 DOI: 10.1101/2021.09.03.458735] [Reference Citation Analysis]
20 Darzianiazizi M, Mehrani Y, Chan L, Mould RC, Kulkarni RR, Sharif S, Bridle BW, Karimi K. Type I Interferon α/β Receptor-Mediated Signaling Negatively Regulates Antiviral Cytokine Responses in Murine Bone-Marrow-Derived Mast Cells and Protects the Cells from Virus-Induced Cell Death. Int J Mol Sci 2020;21:E9041. [PMID: 33261178 DOI: 10.3390/ijms21239041] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
21 Bhatia B, Meade-White K, Haddock E, Feldmann F, Marzi A, Feldmann H. A live-attenuated viral vector vaccine protects mice against lethal challenge with Kyasanur Forest disease virus. NPJ Vaccines 2021;6:152. [PMID: 34907224 DOI: 10.1038/s41541-021-00416-2] [Reference Citation Analysis]
22 Furuyama W, Nanbo A, Maruyama J, Marzi A, Takada A. A complement component C1q-mediated mechanism of antibody-dependent enhancement of Ebola virus infection. PLoS Negl Trop Dis 2020;14:e0008602. [PMID: 32886656 DOI: 10.1371/journal.pntd.0008602] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
23 Nuismer SL, C Layman N, Redwood AJ, Chan B, Bull JJ. Methods for measuring the evolutionary stability of engineered genomes to improve their longevity. Synth Biol (Oxf) 2021;6:ysab018. [PMID: 34712842 DOI: 10.1093/synbio/ysab018] [Reference Citation Analysis]
24 Bhatia B, Furuyama W, Hoenen T, Feldmann H, Marzi A. Ebola Virus Glycoprotein Domains Associated with Protective Efficacy. Vaccines (Basel) 2021;9:630. [PMID: 34200548 DOI: 10.3390/vaccines9060630] [Reference Citation Analysis]
25 Hufert F, Spiegel M. [Coronavirus: from common cold to severe pulmonary failure]. Monatsschr Kinderheilkd 2020;:1-11. [PMID: 32292213 DOI: 10.1007/s00112-020-00910-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
26 Lundstrom K. Self-replicating vehicles based on negative strand RNA viruses. Cancer Gene Ther 2022. [PMID: 35169298 DOI: 10.1038/s41417-022-00436-7] [Reference Citation Analysis]